NCT06652737 - Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Malaria FalciparumMalaria Infection

Interventions

BIOLOGICAL

PfSPZ-LARC2 Vaccine

The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)

BIOLOGICAL

Normal Saline (Placebo)

Normal Saline Placebo

Trial Locations (1)

06

RECRUITING

Groupe de Recherche Action en Santé (GRAS) / Unité de Recherche Clinique de Sabou, Ouagadougou

All Listed Sponsors

collaborator

University of Maryland, Baltimore

OTHER

collaborator

Groupe de Recherche Action en Sante

OTHER

collaborator

Seattle Children's Hospital

OTHER

lead

Sanaria Inc.

INDUSTRY